Fimasartan, a novel angiotensin II receptor antagonist |
| |
Authors: | Je Hak Kim Joo Han Lee Soo Heui Paik Ji Han Kim Yong Ha Chi |
| |
Affiliation: | Central Research Institute, Boryung Pharmaceutical Co., Ltd., Ansan 425-839, Korea. jayhkim@boryung.co.kr |
| |
Abstract: | Fimasartan (Kanarb?), an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound that was developed by Boryung Pharm. Co., Ltd. Among numerous synthetic derivatives, fimasartan was chosen as a new drug candidate through in vitro and in vivo screening studies. Pharmadynamic-pharmacokinetic properties and safety profiles were determined in a series of nonclinical and clinical studies. Fimasartan is a new angiotensin receptor blocker, and the first new molecular entity acting on cardiovascular system approved by Korean Food and Drug Administration for the treatment of essential hypertension in September 2010. Further development process for combination therapy and overseas registration is currently ongoing. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|